Gilead Sciences, Inc. (BIT:1GILD)
102.70
-0.94 (-0.91%)
At close: Oct 31, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B USD in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.20
Revenue / Employee
$1.65M
Employees
17,600
Market Cap
128.99B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Recordati Industria Chimica e Farmaceutica | 2.48B |
| Amplifon | 2.41B |
| DiaSorin | 1.22B |
| Safilo Group | 998.89M |
| EL.En. | 579.71M |
| Svas Biosana | 134.95M |
| Pharmanutra | 122.25M |
| Philogen | 84.66M |